THOUSAND OAKS, Calif., Aug. 20, 2024 /PRNewswire/ -- Amgen (AMGN) today announced Otezla ® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug ...

THOUSAND OAKS, Calif., May 30, 2023 /PRNewswire/ -- Amgen (AMGN) today announced new research examining the use of Otezla ® (apremilast) in psoriatic arthritis, including the Phase 4 MOSAIC study and ...

Otezla is the first oral therapy approved for moderate to severe plaque psoriasis in this patient population. The Food and Drug Administration (FDA) has expanded the approval of Otezla ® (apremilast) ...

Otezla (apremilast) is a brand-name oral tablet that’s prescribed for conditions such as psoriatic arthritis. The drug’s cost with and without insurance can depend on several factors, such as whether ...

THOUSAND OAKS, Calif., Aug. 20, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced Otezla ® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug ...

MOSAIC Study is First to use MRI to Assess Inflammation in Peripheral Joints and Entheses in Psoriatic Arthritis Patients Exploratory Analysis Examines Effects of Otezla on Cardiometabolic Parameters ...

Otezla ® (apremilast) is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP ...